148 results on '"Minini, Pascal"'
Search Results
2. Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
3. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial
4. The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD
5. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials
6. Venglustat in GBA1-related Parkinson's disease – Authors' reply
7. A Case Study of 2-Stage Seamless Adaptive Sample Size Re-Estimation Design with Efficacy Interim AnalysisWhen Slope Is the Primary Endpoint.
8. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia
9. Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)
10. A Case Study of 2-stage Seamless Adaptive Sample Size Re-Estimation Design with Efficacy Interim analysis When Slope is the Primary Endpoint
11. Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials
12. Two years of venglustat combined with imiglucerase shows continued positive effects on neurological features and brain connectivity in adults with Gaucher disease type 3
13. Changes in hematologic and visceral manifestations over time following imiglucerase initiation in Gaucher disease type 1 and type 3 pediatric patients in the ICGG Gaucher Registry
14. Venglustat, a novel brain-penetrant glucosylceramide synthase inhibitor, for Gaucher disease type 3: Phase 3 LEAP2MONO trial design
15. Fine-motor functioning and its relevance to activities of daily living in adults with late-onset GM2 gangliosidosis: Analysis of baseline data of AMETHIST trial
16. AMETHIST: Baseline characteristics from a phase 3 trial of venglustat, a novel brain-penetrant glucosylceramide synthase inhibitor, in GM2-gangliosidoses and related diseases
17. Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial
18. Bleeding Risk in Patients With Atrial Fibrillation: The AMADEUS Study
19. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis
20. Venglustat, a novel brain-penetrant glucosylceramide synthase inhibitor, for GM2 gangliosidosis and related diseases: Phase 3 AMETHIST trial design
21. Pharmacokinetics and biomarker responses in patients with Gaucher disease type 3 or -associated Parkinson's disease treated with venglustat
22. A study to evaluate the effect of venglustat on neuropathic and abdominal pain in symptomatic adult patients with Fabry disease
23. Venglustat in GBA1-related Parkinson's disease – Authors' reply
24. Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial.
25. Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes: The TAO Randomized Clinical Trial
26. Oral venglustat in Parkinson disease patients with a mutation: Study design of part 2 of the MOVES-PD trial and patient characteristics
27. Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients With Parkinson's Disease and a GBA Mutation: Results From Part 1 of the Randomised, Double-Blinded, Placebo-Controlled MOVES-PD Trial
28. Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in the Japanese and the Rest of the World Parkinson’s Disease Population With a GBA Mutation: Results from Part 1 of the MOVES-PD Study (809)
29. Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial.
30. Sensitivity analysis of longitudinal binary data with non-monotone missing values
31. Relation between heart rate variability and training load in middle-distance runners
32. Natural history of late-onset GM2 gangliosidosis: Four years of data collected at NTSAD annual conferences
33. Safety, pharmacokinetics, and pharmacodynamics of oral venglustat in Parkinson disease patients with a GBA mutation from Japan and the rest of the world: Results from part 1 of the MOVES-PD study
34. SaO002QUANTITATIVE RELATIONSHIP BETWEEN TKV GROWTH RATE AND eGFR RATE OF DECLINE IN ADPKD PATIENTS
35. Pharmacokinetics and biomarker responses in patients with Gaucher disease type 3 or GBA-associated Parkinson's disease treated with venglustat
36. Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBAMutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial
37. Venglustat in adult Gaucher disease type 3: Preliminary safety, pharmacology, and exploratory efficacy from a phase 2 trial in combination with imiglucerase (LEAP)
38. Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson disease patients with a GBA mutation
39. Oral venglustat in Parkinson disease patients with a GBA mutation: Study design of part 2 of the MOVES-PD trial and patient characteristics
40. Functional performance in late-onset GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases), longitudinal data over 3 consecutive years
41. Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia
42. Reductions in Atherogenic Lipids and Major Cardiovascular Events
43. Inverse Relationship Between Major Adverse Cardiovascular Events and non-High-Density Lipoprotein Cholesterol and Apolipoprotein B in Phase 3 Trials of Alirocumab
44. RELATIONSHIP BETWEEN PERCENTAGE REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND MAJOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AMONG PATIENTS TREATED WITH STATINS +/- ALIROCUMAB OR EZETIMIBE IN THE PHASE 3 ODYSSEY TRIALS
45. RELATIONSHIP BETWEEN MAJOR ADVERSE CARDIOVASCULAR EVENTS AND ACHIEVED LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN PHASE 3 ODYSSEY TRIALS OF ALIROCUMAB VERSUS CONTROL
46. EFFICACY AND SAFETY OF ALIROCUMAB STRATIFIED BY AGE IN PHASE 3 TRIALS
47. Economic Burden of Hepatitis in South Korea
48. Abstract 17099: Additional LDL-C Reduction Achieved With Alirocumab Dose Increase on Background Statin
49. NET CLINICAL BENEFIT OF COMBINATION ANTICOAGULANT AND ANTIPLATELET THERAPY VERSUS ANTICOAGULATION ALONE IN ATRIAL FIBRILLATION PATIENTS: RESULTS FROM THE AMADEUS TRIAL
50. Du bon usage des tests dans les essays cliniques
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.